Contact Us: Sales@finabio.com

Conjugate Vaccine Services

FinaBio is expert in the design and synthesis of conjugate vaccines, linking proteins to antigens such as polysaccharides, oligosaccharides, peptides and haptens.

Andrew Lees, PhD, Scientific Director, is a leader in the field of conjugate vaccine chemistry.  He is known for his introduction of the widely used CDAP chemistry to the synthesis of conjugate vaccines. Fina Bio has the scientific knowledge needed for optimization of CDAP-based conjugation.

FinaBio offers proprietary methods for high yield reductive amination conjugation based on oxime chemistry, a superior alternative to widely used reductive amination.

Our Conjugate Vaccine Services:

  • Research
  • Consulting
  • Protocol development for clients
  • Training client scientists
  • Supporting the implementation of technology at the client’s site

News

  • About FinaBio
    Whitepaper
    Characterization of Fina Biosolutions’ Amino-Dextran
  • About FinaBio

Address

9430 Key West Ave., Suite 200
Rockville, MD 20850
877-346-2246 (877-FinaBio)
301-633-0464 (Andrew Lees, Scientific Director)
Finabio.net
ALees@FinaBio.com

About Us

Fina Biosolutions, LLC was founded in 2006 by Dr. Andrew Lees with an initial focus on helping emerging market vaccine manufacturers learn to make affordable conjugate vaccines. FinaBio has since grown to offer a variety of bioconjugation and protein services. The company is located in the heart of Maryland’s biotechnology corridor.